Posted by Michael Wonder on 30 Apr 2019
Schedule of Pharmaceutical Benefits - 1 May 2019 update
1 May 2019 - The May 2019 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.
The May issue of the Schedule includes a number of new/revised listings:
- Avelumab (Bavencio) - new medicine
- Inotuzumab ozogamicin (Besponsa) - new medicine
- Palbociclib (Ibrance) - new medicine
- Sapropterin dihydrochloride (Kuvan) - new indication
- Tofacitinib citrate (Xeljanz) - new indication
